    |
||||
 |
||||
 |
||||
News CryoCath Announces Addition to Board of DirectorsMontreal, Quebec, Canada - August 30, 2007 - CryoCath Technologies Inc., the global leader in cryotherapy products to treat
cardiovascular disease, today announced the addition of Jesse Penn to the
Company’s Board of Directors. During his successful tenure with Johnson & Johnson, Mr. Penn served in many different senior executive roles. These included Vice President, Global Operations at various Johnson & Johnson businesses, including Cordis Corporation, Vice President Global Marketing at Ethicon, and President Cordis Cardiology. Previously, Mr. Penn served on the Board of Advisors for the Howard University Business School and he currently sits on the Board of Directors for DFB Pharmaceuticals, Inc. Mr. Penn received a Bachelor of Science degree in Electrical Engineering from Howard University and graduated from the Harvard University Program for Management Development. About Medtronic CryoCathCryoCath - www.cryocath.com - is a medical technology company that leads the
world in cryotherapy products to treat cardiovascular disease. With a priority
focus on providing physicians with a complete solution of catheter products to
treat cardiac arrhythmias, CryoCath has multiple products approved in the U.S.,
across Europe and several ROW countries. The Company is developing additional
products to expand its pipeline of products to treat cardiac
arrhythmias. For further information, please contact:
|
||||
|
||||
